Gladys Rodriguez,MD, FASCO

Proud to be Puerto Rican, mother, wife and oncologist, representing community oncologist @ASCO BOD 21-25, @TheStartcenterforcancercare. Opinions are my own.

[Gladys Rodriguez,MD, FASCO @RodriguezGIMD]

I am honor to join @NarjustDumaMD and @ASCO @ConquerCancerFd to fund a YIA for Latinas in oncology https://t.co/QADuUWX4th @SandraSwainMD @EdithPerezMD @ASCOPres Please help us reach the goal! @HemOncWomenDocs

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Wow- 🤯 I thought summarizing one #ASCO26 presentation with character limits was a challenge.

@VKaklamani with a pretty good attempt to summarize all of breast into one tweet 😂 👏 🤩

[Paolo Tarantino @PTarantinoMD]

What % of patients with HER2+ eBC and residual disease are eligible for T-DXd according to the DB-05 criteria?

👉48%
👉the majority of patients (lower risk) remain eligible for T-DM1
👉T-DM1-only eligible patients experienced favorable real-world outcomes, despite having RD

[Dr Rishabh Jain @DrRishabhOnco]

15-year SOFT/TEXT update confirms what many of us already sensed in clinic:

Not every premenopausal HR+ breast cancer needs endocrine escalation.
But the youngest, highest-risk patients absolutely do. 🎯

🔹 Exemestane + OFS continued to reduce distant recurrence vs tamoxifen + OFS
🔹 Biggest absolute benefit seen in:
• Age <35
• Grade 3 disease
• HER2-negative tumors
• Prior chemotherapy cohorts

In women <35 years with HER2-negative disease:
15-year OS:
➡️ 82.5% with exemestane + OFS
➡️ 68.1% with tamoxifen alone

That is not a marginal difference.

The real message from SOFT/TEXT in 2026:
Risk-adapted endocrine therapy matters more than ever. 📈

#ASCO26 #bcsm #OncoTwitter @OncoAlert @myesmo @esmo_open @ASCO

[Jame Abraham, MD, FACP @jamecancerdoc]

The most trusted voice in cancer care @ASCOPost It is an honor for me to be appointed as the Senior Deputy Editor of @ASCOPost The voice of @ASCO ! Grateful to the very talented editorial board, leadership of Dr. Jim Armitage EIC, @caraglynn01 and Angela Cochran!

[Mabel Mardones, MD @mabelonc]

sometimes just giving patients a choice between what kind of chemo and letting them know this is better than none at all is more important that what type of regimen. This trial supports patient centric decisions

[Sarah Premji, MD @SPremji7866]

@ErikaHamilton9 beautifully presents additional efficacy and safety from HER2CLIMB05, at median follow up of 23 months mPFS was prolonged by 9 month. In HR- mPFS 12.6 mo improved to 24.9 mos, in HR+, mPFS improved from 18.1 mo to 25 mo, those with and without baseline brains mets still derived benefit, and denovo and recurrent disease also still derived benefit. No new safety signals. @OncoAlert
@SCRIOncology @SarahCannonDocs

[Matteo Lambertini, MD PhD @matteolambe]

These are really clinically relevant and practice changing data on how to optimize #denosumab use in patients with bone metastases: induction with 4 monthly administrations then every 3 months

#ASCO26 @ASCO @OncoAlert @valeguarneri

[Dr. Estela Rodriguez @Latinamd]

#ASCO26 Great dinner with Women in Thoracic Oncology. Grateful to share ideas, mentorship, and friendship with such an inspiring group of leaders. @ASCO is not only about science and innovation, but also about lifting each other up and building community. #WomenInOncology #LungCancer #SheforShe

[Yakup Ergün @dr_yakupergun]

#ASCO26 | SERENA-6

Early switch to camizestrant + CDK4/6i at the emergence of an ESR1 mutation also improved PFS2 versus continuing AI + CDK4/6i.

PFS2: 25.7 vs 19.1 months✅️
HR 0.63, p=0.0037

The strategy is reasonable: intervene with ctDNA before waiting for radiologic progression.

But there is a design issue: if crossover to camizestrant at radiologic progression had been mandatory, we could have understood the true value of early switching at molecular relapse much more clearly.

Looking forward to the discussion.

[Julie Gralow @jrgralow]

This excellent #asco26 ed session on Time to Trial Activation featuring @FDAOncology @NCIDirector @KimrynRathmell &amp; @Dee_Anna_Smith is available around the paywall - scroll down in this link: (and watch opening ceremony and @ASCO Voices talks as well!)

https://t.co/nagSoBQBYj

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

My #ASCO26 #FitCheck: spent Day 4 PM &amp; Day 5 AM streaming sessions in my PJs from my hotel room while catching up on clinical work. I'm happy to have phenomenal colleagues who help cover for small acute issues but in the last 24 hrs I've had 8 plans due. 😅☢️🛠️⚡️🩻#ASCOFashion

[Dr. Estela Rodriguez @Latinamd]

#ASCO26 I never imagined that in the middle of my career I’d be reporting on cancer research advances and helping make them understandable for the lay public—in both English and Spanish. Grateful for the opportunity. @Lung_Cancers @sylvestercancer #CancerResearch #MedTwitter

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

I've waited all #ASCO26 to finally spend time with Dr @NarjustFlorezMD and now it's TIME. 🤜⚡️🤛

[Julie Gralow @jrgralow]

As #asco26 comes to a close, I think the highlight for me was connecting w/3 of my prior @ConquerCancerFd @asco IDEA mentees: Nico from Romania, Yanin from Mexico, &amp; Anyur from Kazakhstan. All 3 have become amazing oncology leaders &amp; are improving cancer care globally. So proud!

[Narjust Florez, MD, FASCO @NarjustFlorezMD]

It’s time!

To bring Lorlatinib to early stage ALK+ lung cancer

#ASCO26 @pfizer @ALKPositiveinc @ALKpositiveINT

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

🌊☀️💨🌎 @DrNogueiraL #ASCO26 climate change worsens risk of cancer due to increased exposure to carcinogens, worsened risks (and outcomes) from extreme weather events, and disproportionately affects vulnerable populations.

We can adapt and mitigate... to reduce suffering.

[Ivy Riano, M.D. @IvyLorena_Md]

@COlazagasti

[Paolo Tarantino @PTarantinoMD]

It was a honor to have the chance to discuss 4 tremendous oral presentations on novel ADCs at #ASCO26.

They tell a clear story: TOPO1 ADCs will soon join the treatment arsenal of SCLC, NEC and GYN cancers.

Many challenges ahead, though. The most key: biomarkers and sequencing.

[Dr. Estela Rodriguez @Latinamd]

#ASCO26 #Day4 and that’s a wrap for me. Every year I enjoy this meeting more. It brings me joy to reconnect with old friends, collaborate with @ASCO committee volunteers, patient advocates, industry partners, and most importantly celebrate the remarkable advances in cancer research and the dedicated people around the world working tirelessly to improve the lives of patients with cancer. #CancerResearch #Oncology #MedTwitter @SylvesterCancer

[Coral Olazagasti, MD @COlazagasti]

Going back to my roots to write w/ my super mentor ⁦@NagashreeSeeth1⁩

Check out our editorial for #ASCODailyNews where we discuss the changes in treatment landscape of #NSCLC w/ TKIs and immunotherapy going from advanced ➡️ adjuvant ➡️ neoadjuvant https://t.co/hulTt6c4Pa